Riskpilot← Back to searchSign inGet full accessBactolife A/S
A/SActiveCVR 38879073Rønnegade 8, 2.Manufacture of other chemical products n.e.c. · NACE 2059Est. 201757 employees
Revenue 2024
DKK -21,7M
EBITDA margin
264.9%
-24% vs 2023
Equity ratio
92.4%
Financial strength
Net profit 2024
DKK -49,2M
-8% vs 2023
| Revenue | DKK -21,7M | — |
| EBITDA | DKK -57,4M | -24% |
| Net profit | DKK -49,2M | -8% |
| Total assets | DKK 175,9M | -24% |
| Equity | DKK 162,5M | -23% |
| Employees | 57 | — |
Legal name
Bactolife A/S
CVR number
38879073
Legal form
Aktieselskab
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
10. august 2017
Share capital
DKK 1.074.533
Employees
57 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og bestyrelsesformanden, af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er udvikling af produkter rettet mod smitsomme sygdomme og anden forretningsmæssig aktivitet beslægtet hermed.
Address
Rønnegade 8, 2.
Email
info@bactolife.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | -683 | -1.318 | -1.306 | 1.484 | 333 | 0 | -21.682 |
| Staff expenses | -771 | -595 | -2.479 | -8.538 | -19.094 | -29.705 | -35.749 |
| EBITDA | -1.453 | -1.913 | -3.786 | -10.613 | -28.211 | -46.499 | -57.431 |
| Depreciation & amort. | -0 | -0 | -0 | -77 | -599 | -1.124 | -1.767 |
| EBIT | -1.453 | -1.913 | -3.786 | -10.691 | -28.810 | -47.623 | -59.198 |
| Net financials | -24 | -145 | -99 | -126 | -3.035 | -3.458 | 4.469 |
| Profit before tax | -1.478 | -2.058 | -3.884 | -10.817 | -31.845 | -51.081 | -54.729 |
| Tax | -298 | -412 | -1.167 | -2.592 | -4.277 | -5.500 | -5.500 |
| Net profit | -1.180 | -1.646 | -2.717 | -8.224 | -27.568 | -45.581 | -49.229 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 894 | 991 | 9.642 | 57.513 | 84.338 | 232.625 | 175.931 |
| Equity | -217 | -1.235 | 6.938 | 51.457 | 23.889 | 211.744 | 162.515 |
| Long-term debt | 0 | 0 | 0 | 0 | 38.857 | 0 | 0 |
| Short-term debt | 1.111 | 2.226 | 2.704 | 5.714 | 21.191 | 19.830 | 11.872 |
| Total debt | 1.111 | 2.226 | 2.704 | 5.714 | 60.048 | 19.830 | 11.872 |
EBITDA margin
-5743118800.0%
This company
15.8%
Market median
-36348853265% vs market
20182024
Equity ratio
92.4%
This company
38.2%
Market median
+142% vs market
20182024
Return on equity
-30.3%
This company
18.4%
Market median
-265% vs market
20182024
Net profit margin
-4922935100.0%
This company
8.1%
Market median
-60776976643% vs market
20182024
Asset turnover
-0.12×
This company
1.12×
Market median
-111% vs market
20182024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2017-08-10 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CS Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 20.0% | 20.0% | 2025 |
| Individual | 20.0% | 20.0% | 2025 | |
Danmarks Eksport- og Investeringsfond | Company | 5.0% | 5.0% | 2025 |
SELFINVEST ApS | Company | 5.0% | 5.0% | 2025 |
MR BIOINVEST ApS | Company | 5.0% | 5.0% | 2025 |
| Individual | 5.0% | 5.0% | 2023 | |
| Individual | 5.0% | 5.0% | 2021 | |
LILLE FREDERIKSLUND INVEST ApS | Company | 5.0% | 5.0% | 2023 |
NOVOZYMES A/S | Company | 5.0% | 5.0% | 2023 |
| Individual | 10.0% | 10.0% | 2018 | |
| Individual | 5.0% | 5.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MR BIOINVEST ApS
Bactolife A/S Board members of Bactolife A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claus Sebastian Søderberg | Chief Executive Officer | 0 companies |
| Mads Aage Laustsen | Board of Directors | 0 companies |
| Sara Sande | Board of Directors | 0 companies |
| Sophia Andrea Helga Heyde | Board of Directors | 0 companies |
| Frank Julian Zachmann | Board of Directors | 0 companies |
| Morten Jensen | Board of Directors | 0 companies |
| Morten Aleksandr Engel | Board of Directors | 0 companies |
| Per Falholt | Board of Directors | 0 companies |
| Rhonda Doyce Hoffman | Board of Directors | 0 companies |
| Jørgen Rugholm Jensen | Chairman | 0 companies |
| Andreas Hougaard Laustsen-Kiel | Board of Directors | 0 companies |
| Donna Margaret Parr | Board of Directors | 0 companies |